Recent Updates
Recently added Catalysts
IMCR Positive Sentiment Score: 70/100

Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference

Key Takeaway: Immunocore Holdings plc is set to present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on January 15, 2025. The live presentation will showcase the company's efforts in developing transformative immunotherapies, including their proprietary ImmTAX platform. Immunocore is advancing multiple clinical-stage programs in oncology and infectious diseases, highlighting their commitment to improving patient outcomes. The event will also be available for streaming on their website.

Market Sentiment Analysis

POSITIVE FACTORS

  • Immunocore is participating in a prestigious healthcare conference.
  • The company is pioneering innovative immunomodulating medicines.
  • They have a deep pipeline of clinical programs across multiple therapeutic areas.

Full Press Release Details

Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 6 January 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in in a presentation at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California.
The presentation is scheduled for Wednesday, January 15, 2025, at 8:15 a.m. Pacific Standard Time (PST).
The presentation will be webcast live and can be accessed by visiting ‘Events & Presentations’, under ‘Events’, via the ‘Investors’ section of Immunocore’s website at www.immunocore.com. Following the event, a replay of the presentation will be made available for a limited time.
Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune, and infectious disease. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.
Sébastien Desprez, Head of Communications
T: +44 (0) 7458030732
Follow on Twitter: @Immunocore
Clayton Robertson, Head of Investor Relations
T: +1 (215) 384-4781

Tags

Frequently Asked Questions

When will Immunocore present at the J.P. Morgan Conference?

Immunocore will present on January 15, 2025, at 8:15 a.m. PST.

Where can I watch the Immunocore presentation?

The presentation will be webcast live on Immunocore's website under ‘Events & Presentations’.

What distinguishes Immunocore's therapies?

Immunocore develops a novel class of TCR bispecific immunotherapies called ImmTAX.

What diseases does Immunocore target?

Immunocore targets cancer, autoimmune diseases, and infectious diseases.

What is Immunocore's leading therapy?

The leading therapy is KIMMTRAK, approved for certain patients with uveal melanoma.

Last updated: Jan 6, 2025